Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

659
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
659
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

7.7K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
7.7K
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

764
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
764
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

943
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
943
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

1.9K
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.9K
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

1.2K
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In adults with acute VTE, apixaban vs. rivaroxaban reduced clinically relevant bleeding at 3 mo.

Annals of internal medicine·2026
Same author

External Validation of the JAKPOT Score for Diagnosing <i>JAK2</i>-Positive Erythrocytosis: A Retrospective Cohort Study.

Journal of clinical medicine·2025
Same author

A Case of Methemoglobinemia and Hemolysis from Sodium Chlorite Ingestion.

Clinical medicine & research·2025
Same author

Transfusion of Fresh Frozen Plasma and Platelets in Critically Ill Adults: An American College of Chest Physicians Clinical Practice Guideline.

Chest·2025
Same author

Red Blood Cell Transfusion in Critically Ill Adults: An American College of Chest Physicians Clinical Practice Guideline.

Chest·2024
Same author

Evaluation of a diagnostic platelet aggregation test strategy for platelet rich plasma samples with low platelet counts.

International journal of laboratory hematology·2023
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Related Experiment Video

Updated: May 5, 2026

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2
10:31

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2

Published on: September 26, 2025

672

Antiphospholipid syndrome.

Wendy Lim1

  • 11Department of Medicine, McMaster University, Hamilton, ON.

Hematology. American Society of Hematology. Education Program
|December 10, 2013
PubMed
Summary
This summary is machine-generated.

Antiphospholipid syndrome (APS) involves blood clots and pregnancy issues due to antiphospholipid antibodies (aPLs). Triple positivity for aPLs indicates higher risk, guiding treatment decisions for this serious condition.

More Related Videos

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

1.3K
Fluorescence-Based Measurements of Phosphatidylserine/Phosphatidylinositol 4-Phosphate Exchange Between Membranes
08:49

Fluorescence-Based Measurements of Phosphatidylserine/Phosphatidylinositol 4-Phosphate Exchange Between Membranes

Published on: March 14, 2021

3.5K

Related Experiment Videos

Last Updated: May 5, 2026

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2
10:31

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2

Published on: September 26, 2025

672
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

1.3K
Fluorescence-Based Measurements of Phosphatidylserine/Phosphatidylinositol 4-Phosphate Exchange Between Membranes
08:49

Fluorescence-Based Measurements of Phosphatidylserine/Phosphatidylinositol 4-Phosphate Exchange Between Membranes

Published on: March 14, 2021

3.5K

Area of Science:

  • Immunology
  • Hematology
  • Obstetrics

Background:

  • Antiphospholipid syndrome (APS) is characterized by thrombosis or pregnancy complications in patients with antiphospholipid antibodies (aPLs).
  • Catastrophic APS (CAPS) is a severe variant involving rapid microvascular thrombosis and multiorgan failure.
  • Patients with APS face a high risk of recurrent thrombosis, even with anticoagulant therapy, and bleeding complications can arise.

Purpose of the Study:

  • To summarize the clinical presentation and risk stratification of Antiphospholipid Syndrome (APS).
  • To highlight the significance of specific antiphospholipid antibody profiles in predicting thrombotic risk.
  • To underscore the ongoing controversies and future research needs in APS management, particularly anticoagulation.

Main Methods:

  • Review of existing literature on Antiphospholipid Syndrome (APS) diagnosis and management.
  • Analysis of risk factors associated with thrombosis and pregnancy morbidity in APS patients.
  • Discussion of current treatment strategies, including anticoagulation, and their limitations.

Main Results:

  • Persistent antiphospholipid antibodies (aPLs) are key diagnostic markers for APS.
  • Triple aPL positivity (lupus anticoagulant, anticardiolipin, anti-β2GPI) is linked to a significantly higher risk of thrombosis and pregnancy complications.
  • Isolated aPL positivity is associated with a lower thrombotic risk.

Conclusions:

  • Risk stratification based on aPL profile is crucial for managing APS patients.
  • Optimal anticoagulation strategies for APS, especially for arterial and recurrent thrombosis, require further investigation.
  • Future research should focus on refining thrombotic risk assessment and evaluating novel therapeutic approaches for APS.